EXACT SCIENCES CORPEXAS财报
Nasdaq · health care industry
Exact Sciences是总部位于美国威斯康星州麦迪逊的分子诊断企业，专注于早期癌症检测领域。公司核心产品覆盖结直肠癌筛查与预防场景，其中Cologuard是全球首个获批的结直肠癌粪便DNA检测产品，同时还提供其他多种癌症的筛查服务及精准肿瘤检测解决方案。
主要股东
| 股东 | 持股比例 | 股数 | 变动 | 截至 |
|---|---|---|---|---|
| FMR LLC | 11.90% | 22.0M | — | 2024-10-07 |
| The Vanguard Group | 9.71% | 17.6M | — | 2024-02-13 |
| OF ABOVE PERSONS | 8.60% | 15.8M | — | 2024-11-13 |
| Wellington Management Group LLP | 7.93% | 14.7M | ▲ +2.10pp | 2024-11-08 |
| Genomic Health, Inc. | 7.10% | 3.4M | — | 2024-10-04 |
| BlackRock, Inc. | 6.10% | 11.1M | — | 2024-01-29 |
| NOS. OF ABOVE PERSONS | 4.00% | 7.5M | ▼ -5.50pp | 2024-06-07 |
内部人交易
Net 90d: +$0 · buys $0 / sells $0时间范围:
类型:
身份:
| 内部人 | 身份 | 类型 | ||||
|---|---|---|---|---|---|---|
| 2026-03-23 | Conroy Kevin T | President and CEO | Grant | 119.3K | $0.00 | $0 |
| 2026-03-23 | Conroy Kevin T | President and CEO | Disposition | 1.40M | — | — |
| 2026-03-23 | Conroy Kevin T | President and CEO | Disposition | 29.1K | — | — |
| 2026-03-23 | Conroy Kevin T | President and CEO | Disposition | 46.5K | — | — |
| 2026-03-23 | Conroy Kevin T | President and CEO | Disposition | 86.8K | — | — |
| 2026-03-23 | Conroy Kevin T | President and CEO | Disposition | 117.4K | — | — |
| 2026-03-23 | James Herriott | SVP, General Counsel & Sec | Disposition | 68.2K | — | — |
| 2026-03-23 | James Herriott | SVP, General Counsel & Sec | Disposition | 1.8K | — | — |
| 2026-03-23 | Aaron Bloomer | EVP, Chief Financial Officer | Grant | 89.9K | $0.00 | $0 |
| 2026-03-23 | Aaron Bloomer | EVP, Chief Financial Officer | Disposition | 138.7K | — | — |
1–10 of 43
第 1 页 / 共 5 页